Comparison
Lanreotid vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
57773-63-4
Molecular weight
1096.34 g/mol
1311.45 g/mol
Half-life
no data
3 h
Sequence
no data
pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
4
Effects recorded
2
3
Open conflicts
1
0
Documented adverse events
2
3
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and Triptorelin?
- Lanreotid is classified as "Research other", while Triptorelin is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Triptorelin?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human RCT" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Triptorelin in Germany and the United States?
- Germany: Lanreotid — Prescription, Triptorelin — Prescription. United States: Lanreotid — Prescription, Triptorelin — Prescription. These are factual summaries with source and review date on the individual pages.